Some areas of AAO.org are temporarily unavailable. We apologize for the inconvenience and are working to restore access.

  •   
    By Carl Regillo, MD, FACS; Baruch Kuppermann, MD, PhD
    2012 Annual Scientific Meeting of the American Society of Retina Specialists
    Comprehensive Ophthalmology, Retina/Vitreous

    Drs. Carl Regillo and Baruch Kuppermann, lead investigators for the MIVI-Trust studies, discuss the safety and efficacy of ocriplasmin for resolution of vitreomacular traction and closure of macular hole. They presented their findings at the 2012 Annual Scientific Meeting of the American Society of Retina Specialists (ASRS).

    Financial Disclosures: Dr. Regillo receives consulting fees from Alcon Laboratories, Genentech, Novartis, and QLT Phototherapeutics.
    Dr. Kuppermann receives consulting fees or research support from Alimera, Allergan, Allegro, Fovea, Genentech, Glaukos, Novagali, Novartis, Ophthotech, Pfizer, Regeneron Pharmaceuticals, and ThromboGenics.